n Obstetrics and Gynaecology Forum - Trastuzumab (Herceptin™) for the diagnosis and treatment of breast cancer : a review : review article

Volume 18, Issue 4
  • ISSN : 1027-9148



The emergence of targeted therapy for cancer, and more especially for breast cancer, has created high expectations from patients and oncologists. Trastuzumab, better known as Herceptin™, is used for the diagnosis and treatment of tumours carrying the HER-2 oncogene. From the diagnostic point of view, all methods for the assessment of the HER-2 gene or the HER-2 protein have limitations in terms of both technology and cut-off values and have not yet been standardized. Both false positive and false negative assessments are currently not uncommon. The inclusion criteria for treatment with trastuzumab are relatively narrow and the cost per cure is, at present, extremely high. It is therefore essential to have an understanding of the current data about this therapy and of their interpretation.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error